HSD135 Oncologists’ Perceptions of Nivolumab Plus Ipilumumab (NIVO + IPI) As First-Line (1L) Treatment for Microsatellite Instability-High/Mismatch Repair-Deficient (Msi-H/dmmr) Metastatic Colorectal Cancer (Mcrc)
Value in Health（2024）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要